Crescent Biopharma (CBIO) – Analysts’ Weekly Ratings Changes

by · The Cerbat Gem

Crescent Biopharma (NASDAQ: CBIO) recently received a number of ratings updates from brokerages and research firms:

  • 12/8/2025 – Crescent Biopharma had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/6/2025 – Crescent Biopharma was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 12/4/2025 – Crescent Biopharma was given a new $32.00 price target on by analysts at Stifel Nicolaus.
  • 12/1/2025 – Crescent Biopharma had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/24/2025 – Crescent Biopharma had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/18/2025 – Crescent Biopharma had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/16/2025 – Crescent Biopharma was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 11/12/2025 – Crescent Biopharma is now covered by analysts at Weiss Ratings. They set a “sell (e-)” rating on the stock.
  • 11/8/2025 – Crescent Biopharma was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Activity

In other news, Director Fairmount Funds Management Llc bought 1,360,000 shares of Crescent Biopharma stock in a transaction dated Thursday, December 4th. The stock was bought at an average cost of $13.41 per share, for a total transaction of $18,237,600.00. Following the purchase, the director directly owned 2,747,866 shares in the company, valued at approximately $36,848,883.06. This represents a 97.99% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.00% of the company’s stock.

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Read More